1. Home
  2. GKOS vs NXE Comparison

GKOS vs NXE Comparison

Compare GKOS & NXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$121.94

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Nexgen Energy Ltd.

NXE

Nexgen Energy Ltd.

HOLD

Current Price

$12.55

Market Cap

6.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
NXE
Founded
1998
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.2B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
NXE
Price
$121.94
$12.55
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
$130.93
N/A
AVG Volume (30 Days)
728.9K
6.6M
Earning Date
02-17-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$469,820,000.00
N/A
Revenue This Year
$31.33
N/A
Revenue Next Year
$24.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.38
N/A
52 Week Low
$73.16
$3.91
52 Week High
$163.71
$12.69

Technical Indicators

Market Signals
Indicator
GKOS
NXE
Relative Strength Index (RSI) 61.63 79.62
Support Level $93.96 $11.06
Resistance Level $130.23 $11.33
Average True Range (ATR) 5.22 0.46
MACD 0.80 0.14
Stochastic Oscillator 76.76 89.46

Price Performance

Historical Comparison
GKOS
NXE

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About NXE Nexgen Energy Ltd.

NexGen Energy Ltd is an exploration and development entity engaged in acquiring, evaluating, and developing uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin.

Share on Social Networks: